VSBC
Vitaspring Biomedical Co. Ltd.
Going-concern doubt
— flagged Jun 17, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company’s minimal cash balance, recurring operating losses, and significant working capital deficit raise substantial doubt about its ability to continue as a going concern within one year after the financial statements are issued.”View the 10-Q filed Jun 17, 2026
Company with tickers: VSBC
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Trends
Currently-reported figures from the company's XBRL filings · quarters show the discrete three-month figure, never the year-to-date
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $0 | USD | 2026-04-30 | 10-Q | 2026-06-17 |
| Revenue (ASC 606) | — | ||||
| Interest & Dividend Income | — | ||||
| Net Interest Income | — | ||||
| Noninterest Income | — | ||||
| Total Net Revenue | — | ||||
| Premiums Earned (Net) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $14,368 | USD | 2026-04-30 | 10-Q | 2026-06-17 |
| Research & Development | — | ||||
| Operating Income | $-75,844 | USD | 2026-04-30 | 10-Q | 2026-06-17 |
| Net Income | $-75,844 | USD | 2026-04-30 | 10-Q | 2026-06-17 |
| EPS (Basic) | — | ||||
| EPS (Diluted) | $0.00 | USD/shares | 2026-04-30 | 10-Q | 2026-06-17 |